Le médulloblastome : les dernières avancées majeures

[1]  J. Moffat,et al.  Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma. , 2022, Cancer cell.

[2]  Steven J. M. Jones,et al.  Failure of human rhombic lip differentiation underlies medulloblastoma formation , 2022, Nature.

[3]  J. Palmer,et al.  Medulloblastoma in the Modern Era: Review of Contemporary Trials, Molecular Advances, and Updates in Management , 2022, Neurotherapeutics.

[4]  Jennifer L. Hadley,et al.  MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma , 2022, Nature.

[5]  G. Pagès,et al.  Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma , 2021, Cancers.

[6]  S. Leary,et al.  Carboplatin During Craniospinal Radiotherapy for Children With Group 3 Medulloblastoma-A New Standard of Care?-Reply. , 2021, JAMA oncology.

[7]  S. Terezakis,et al.  The Evolving Role of Radiotherapy for Pediatric Cancers With Advancements in Molecular Tumor Characterization and Targeted Therapies , 2021, Frontiers in Oncology.

[8]  M. Erlander,et al.  A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy. , 2021, Neuro-oncology.

[9]  E. Miele,et al.  Cytotoxic effects and tolerability of gemcitabine and axitinib in a xenograft model for c-myc amplified medulloblastoma , 2021, Scientific Reports.

[10]  Y. Kondo,et al.  Newly Established Patient-derived Organoid Model of Intracranial Meningioma. , 2021, Neuro-oncology.

[11]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[12]  M. Martínez-García,et al.  SEOM clinical guideline for management of adult medulloblastoma (2020) , 2021, Clinical and Translational Oncology.

[13]  P. Varlet,et al.  Role of neoadjuvant chemotherapy in metastatic medulloblastoma: a comparative study in 92 children , 2020, Neuro-oncology.

[14]  M. Tartaglia,et al.  Modeling medulloblastoma in vivo and with human cerebellar organoids , 2020, Nature Communications.

[15]  Zev A. Binder,et al.  A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity , 2019, Cell.

[16]  M. Roussel,et al.  Modeling pediatric medulloblastoma , 2019, Brain pathology.

[17]  John A. Calarco,et al.  Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma , 2019, Nature.

[18]  Mariella G. Filbin,et al.  Stalled developmental programs at the root of pediatric brain tumors , 2019, Nature Genetics.

[19]  Michael D. Taylor,et al.  Medulloblastoma in the age of molecular subgroups: a review. , 2019, Journal of neurosurgery. Pediatrics.

[20]  O. Delattre,et al.  An autocrine ActivinB mechanism drives TGFβ/Activin signaling in Group 3 medulloblastoma , 2019, EMBO molecular medicine.

[21]  Volker Hovestadt,et al.  Resolving medulloblastoma cellular architecture by single-cell genomics , 2019, Nature.

[22]  Tara H. W. Dobson,et al.  Preclinical Models of Pediatric Brain Tumors—Forging Ahead , 2018, Bioengineering.

[23]  Emmanuel Barillot,et al.  Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling. , 2018, Cancer cell.

[24]  O. Klein,et al.  Late effects of craniospinal irradiation for medulloblastomas in paediatric patients. , 2018, Neuro-Chirurgie.

[25]  Michael P. Anderson,et al.  Meta‐analysis of the incidence and patterns of second neoplasms after photon craniospinal irradiation in children with medulloblastoma , 2018, Pediatric blood & cancer.

[26]  E. Moding,et al.  Survival impact of postoperative radiotherapy timing in pediatric and adolescent medulloblastoma , 2018, Neuro-oncology.

[27]  Lincoln D. Stein,et al.  Childhood Cerebellar Tumors Mirror Conserved Fetal Transcriptional Programs , 2018, bioRxiv.

[28]  Michael D. Taylor,et al.  The clinical importance of medulloblastoma extent of resection: a systematic review , 2018, Journal of Neuro-Oncology.

[29]  U. Schüller,et al.  Medulloblastoma: experimental models and reality , 2017, Acta Neuropathologica.

[30]  Sirintra Nakjang,et al.  Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study , 2017, The Lancet. Oncology.

[31]  Roland Eils,et al.  The whole-genome landscape of medulloblastoma subtypes , 2017, Nature.

[32]  A. Goldenberg,et al.  Intertumoral Heterogeneity within Medulloblastoma Subgroups. , 2017, Cancer cell.

[33]  P. Burger,et al.  A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high‐risk medulloblastoma (protocol POG 9631): A report from the Children's Oncology Group , 2017, Pediatric blood & cancer.

[34]  R. Bindra,et al.  Postoperative Radiotherapy Patterns of Care and Survival Implications for Medulloblastoma in Young Children. , 2016, JAMA oncology.

[35]  David T. W. Jones,et al.  Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  B. Coyle,et al.  In vitro models of medulloblastoma: Choosing the right tool for the job. , 2016, Journal of biotechnology.

[37]  B. Moore,et al.  Comparing Intelligence Quotient Change After Treatment With Proton Versus Photon Radiation Therapy for Pediatric Brain Tumors. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  A. Brandes,et al.  A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. , 2016, Neuro-oncology.

[39]  Y. Kanemura,et al.  Molecular Classification of Medulloblastoma , 2016, Neurologia medico-chirurgica.

[40]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[41]  M. Kool,et al.  Risk stratification of childhood medulloblastoma in the molecular era: the current consensus , 2016, Acta Neuropathologica.

[42]  Naoki Kagawa,et al.  Prognostic Value of Medulloblastoma Extent of Resection After Accounting for Molecular Subgroup: An Integrated Clinical and Molecular Analysis , 2016, The Lancet. Oncology.

[43]  A. Brandes,et al.  Adjuvant chemotherapy in adult medulloblastoma: is it an option for average-risk patients? , 2016, Journal of Neuro-Oncology.

[44]  C. Beier,et al.  Chemotherapy increases long-term survival in patients with adult medulloblastoma--a literature-based meta-analysis. , 2016, Neuro-oncology.

[45]  B. Yeap,et al.  Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study. , 2016, The Lancet. Oncology.

[46]  Roland Eils,et al.  Active medulloblastoma enhancers reveal subgroup-specific cellular origins , 2016, Nature.

[47]  S. Asgharzadeh,et al.  Pediatric Brain Tumor Cell Lines , 2015, Journal of cellular biochemistry.

[48]  David T. W. Jones,et al.  Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. , 2013, The Lancet. Oncology.

[49]  S. Croul,et al.  Medulloblastoma: recurrence and metastasis. , 2013, CNS oncology.

[50]  H. Wahba,et al.  Adjuvant chemotherapy after reduced craniospinal irradiation dose in children with average-risk medulloblastoma: a 5-year follow-up study. , 2013, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[51]  Soo Hyun Lee,et al.  Reduced-dose craniospinal radiotherapy followed by tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk medulloblastoma. , 2013, Neuro-oncology.

[52]  Douglas C. Miller,et al.  Induction chemotherapy and conformal radiation therapy for very young children with nonmetastatic medulloblastoma: Children's Oncology Group study P9934. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  Rolf Bjerkvig,et al.  In vivo models of primary brain tumors: pitfalls and perspectives , 2012, Neuro-oncology.

[54]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.

[55]  J. Mesirov,et al.  Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  R. Guillevin,et al.  [Medulloblastomas: review]. , 2011, Revue neurologique.

[57]  Yiai Tong,et al.  Subtypes of medulloblastoma have distinct developmental origins , 2010, Nature.

[58]  N. Boddaert,et al.  Injuries to inferior vermis and dentate nuclei predict poor neurological and neuropsychological outcome in children with malignant posterior fossa tumors , 2009, Cancer.

[59]  Dirk Troost,et al.  Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features , 2008, PloS one.

[60]  J. Finlay,et al.  Outcome of children less than three years old at diagnosis with non‐metastatic medulloblastoma treated with chemotherapy on the “Head Start” I and II protocols , 2008, Pediatric blood & cancer.

[61]  D. Ellison,et al.  The origins of medulloblastoma subtypes. , 2008, Annual review of pathology.

[62]  A. Brandes,et al.  Long‐term results of a prospective study on the treatment of medulloblastoma in adults , 2007, Cancer.

[63]  T. Merchant,et al.  Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. , 2006, The Lancet. Oncology.

[64]  T. Curran,et al.  Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  P. Duffner.  Long-Term Effects of Radiation Therapy on Cognitive and Endocrine Function in Children With Leukemia and Brain Tumors , 2004, The neurologist.

[66]  Heather L. Miller,et al.  A molecular fingerprint for medulloblastoma. , 2003, Cancer research.

[67]  G. Reifenberger,et al.  The WHO Classification of Tumors of the Nervous System , 2002, Journal of neuropathology and experimental neurology.

[68]  J. Krischer,et al.  Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  L. Rorke,et al.  Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  J W Goldwein,et al.  Whole-brain irradiation and decline in intelligence: the influence of dose and age on IQ score. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  P. Bailey,et al.  MEDULLOBLASTOMA CEREBELLI: A COMMON TYPE OF MIDCEREBELLAR GLIOMA OF CHILDHOOD , 1925 .